IMA (ImageneBio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
ImageneBio, Inc. Common Stock (IMA) is a publicly traded Healthcare sector company. As of May 21, 2026, IMA trades at $5.41 with a market cap of $63.73M and a P/E ratio of -0.56. IMA moved +0.00% today. Year to date, IMA is -15.60%; over the trailing twelve months it is flat. Its 52-week range spans $3.94 to $18.00. Analyst consensus is buy with an average price target of $13.00. Rallies surfaces IMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns IMA stock?
Hedge funds tracked by Rallies that own IMA include Orbimed Advisors and Berkshire Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ImageneBio, Inc. Common Stock.
IMA Key Metrics
Key financial metrics for IMA
Metric
Value
Price
$5.41
Market Cap
$63.73M
P/E Ratio
-0.56
EPS
$-9.64
Dividend Yield
0.00%
52-Week High
$18.00
52-Week Low
$3.94
Volume
0
Avg Volume
0
Revenue (TTM)
$800.00K
Net Income
$-45.35M
Gross Margin
0.00%
Top Hedge Funds Holding IMA
Orbimed Advisors holds 378.56K shares of IMA, changed +0.00% as of Mar 31, 2026.
Berkshire Asset holds 20.00K shares of IMA, changed +0.00% as of Jun 30, 2025.
Hedge funds tracked by Rallies that own IMA include Orbimed Advisors and Berkshire Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ImageneBio, Inc. Common Stock.
Does Rallies show 13F holders for IMA?
Yes. Rallies tracks hedge fund and 13F ownership data for IMA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IMA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IMA. It does not provide personalized investment advice.
